Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2016 | How daratumumab will change the treatment of multiple myeloma

Antonio Palumbo • 3 Jun 2016
EHA 2016
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide

Antonio Palumbo, MD from the University of Turin, Turin, Italy discusses the place of daratumumab in the current treatment landscape of multiple myeloma (MM). According to Dr Palumbo, daratumumab will change the treatment paradigm and will be combined to bortezomib and dexamethasone or lenalidomide and dexamethasone.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Antonio Palumbo

Early treatment and novel therapeutic targets for multiple myeloma 10:48
Early treatment and novel therapeutic targets for multiple myeloma
Antonio Palumbo et al. • 11 Apr 2015
Perspectives on future paths to cure multiple myeloma 1:36
Perspectives on future paths to cure multiple myeloma
Antonio Palumbo • 22 Apr 2016
Frontline therapy for multiple myeloma 1:27
Frontline therapy for multiple myeloma
Antonio Palumbo • 30 Apr 2016
Definitions of smouldering myeloma and when to treat 1:38
Definitions of smouldering myeloma and when to treat
Antonio Palumbo • 29 Apr 2016

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals